ZBH

Zimmer Biomet Holdings, Inc. - Q1 2025 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Zimmer Biomet Holdings, Inc. is a global medical technology company designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, and digital surgical technologies. The company operates through three reportable segments: Americas, EMEA, and Asia Pacific.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 1.1% year-over-year, driven by market growth and new product introductions. This growth was partially offset by a 1.2% negative impact from foreign currency exchange rates.
• Profitability: Operating profit increased 9.9% to $292.3 million. This improvement was primarily due to a significant reduction in restructuring charges ($36.0 million in Q1 2025 vs. $124.4 million in Q1 2024).
• Cost Pressures: Cost of products sold increased as a percentage of sales (28.8% vs. 27.1%) due to inflation and higher manufacturing costs. SG&A expenses also rose due to bad debt provisions and investments in marketing and IT.
• Debt Refinancing: The company redeemed $863.0 million of senior notes due in 2025 and issued $1.748 billion in new senior notes (due 2027, 2030, and 2035), resulting in higher interest expense.
• Share Repurchases: The company repurchased $229.8 million of common stock in Q1 2025, compared to $113.6 million in the prior year period.

Guidance, Outlook, and Risks

• 2025 Outlook: Management expects full-year 2025 revenue growth of 5.7% to 8.2%, driven by the Paragon 28 acquisition, market growth, and new products. Foreign currency is expected to have a positive impact of up to 0.5%.
• Earnings Guidance: Net earnings are expected to decrease in 2025 compared to 2024 due to higher acquisition/integration costs, intangible asset amortization, manufacturing inflation, tariffs, and higher interest expenses.
• Tariff Impact: The company anticipates recognizing $60 million to $80 million in additional expenses related to tariffs in 2025, with a more significant impact expected in the second half of the year.
• Restructuring: A new 2025 Restructuring Plan was approved, expected to result in total pre-tax charges of approximately $85 million. The 2023 plan concluded in Q1 2025 with total charges of $117 million.
• Subsequent Event: On April 21, 2025, the company completed the acquisition of Paragon 28, Inc. for approximately $1.4 billion in initial consideration. This transaction introduces integration risks and potential litigation contingencies related to Paragon 28's prior financial restatement.
• Tax Disputes: The IRS has proposed adjustments for tax years 2013-2019, which could result in additional material tax expense (approx. $312 million for 2016-2019) if the company is unsuccessful in defending its position.

Investor Verification Checklist

• Paragon 28 Integration: Verify the timeline and cost of integrating Paragon 28 and the potential impact of the pending securities class action litigation and SEC investigation against Paragon 28.
• Tariff Exposure: Monitor the implementation of proposed tariffs and the company's ability to mitigate the estimated $60-$80 million expense impact.
• Restructuring Execution: Track the realization of cost savings from the 2025, 2023, and 2019 restructuring plans against the incurred charges.
• Debt Service: Assess the impact of higher interest rates on net earnings given the recent refinancing of $1.7 billion in debt.
• Tax Resolution: Follow the status of IRS audits for tax years 2013-2019 and the potential for significant tax adjustments.